MY179845A - Specific biomarker set for non-invasive diagnosis of liver cancer - Google Patents
Specific biomarker set for non-invasive diagnosis of liver cancerInfo
- Publication number
- MY179845A MY179845A MYPI2017001446A MYPI2017001446A MY179845A MY 179845 A MY179845 A MY 179845A MY PI2017001446 A MYPI2017001446 A MY PI2017001446A MY PI2017001446 A MYPI2017001446 A MY PI2017001446A MY 179845 A MY179845 A MY 179845A
- Authority
- MY
- Malaysia
- Prior art keywords
- liver cancer
- tumour
- tumour antigens
- liver
- auto
- Prior art date
Links
- 201000007270 liver cancer Diseases 0.000 title abstract 4
- 208000014018 liver neoplasm Diseases 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 abstract 1
- 102400000686 Endothelin-1 Human genes 0.000 abstract 1
- 101800004490 Endothelin-1 Proteins 0.000 abstract 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract 1
- 206010019695 Hepatic neoplasm Diseases 0.000 abstract 1
- 102100031001 Hepatoma-derived growth factor-related protein 2 Human genes 0.000 abstract 1
- 101100450337 Homo sapiens HDGFL2 gene Proteins 0.000 abstract 1
- 101100177327 Homo sapiens HDGFL3 gene Proteins 0.000 abstract 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 abstract 1
- 101000945751 Homo sapiens Leukocyte cell-derived chemotaxin-2 Proteins 0.000 abstract 1
- 101000697529 Homo sapiens Stathmin-4 Proteins 0.000 abstract 1
- 101000852559 Homo sapiens Thioredoxin Proteins 0.000 abstract 1
- 101000807354 Homo sapiens Ubiquitin-conjugating enzyme E2 C Proteins 0.000 abstract 1
- 102000013691 Interleukin-17 Human genes 0.000 abstract 1
- 108050003558 Interleukin-17 Proteins 0.000 abstract 1
- 102100036679 Interleukin-26 Human genes 0.000 abstract 1
- 102100034762 Leukocyte cell-derived chemotaxin-2 Human genes 0.000 abstract 1
- 108010092801 Midkine Proteins 0.000 abstract 1
- 102000016776 Midkine Human genes 0.000 abstract 1
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 abstract 1
- 101150111584 RHOA gene Proteins 0.000 abstract 1
- 102100028049 Stathmin-4 Human genes 0.000 abstract 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 abstract 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 abstract 1
- 102100036407 Thioredoxin Human genes 0.000 abstract 1
- 102100037256 Ubiquitin-conjugating enzyme E2 C Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 210000002919 epithelial cell Anatomy 0.000 abstract 1
- 210000005228 liver tissue Anatomy 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 238000011002 quantification Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/321,870 US9885718B2 (en) | 2014-07-02 | 2014-07-02 | Specific biomarker set for non-invasive diagnosis of liver cancer |
| US14/321,867 US9506925B2 (en) | 2014-07-02 | 2014-07-02 | Specific biomarker set for non-invasive diagnosis of liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY179845A true MY179845A (en) | 2020-11-18 |
Family
ID=55019816
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017001446A MY179845A (en) | 2014-07-02 | 2014-07-31 | Specific biomarker set for non-invasive diagnosis of liver cancer |
| MYPI2016002278A MY195045A (en) | 2014-07-02 | 2014-07-31 | Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2016002278A MY195045A (en) | 2014-07-02 | 2014-07-31 | Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3164711A4 (enExample) |
| JP (2) | JP2017520763A (enExample) |
| KR (1) | KR102086788B1 (enExample) |
| CN (2) | CN107478842B (enExample) |
| AU (2) | AU2014399919B2 (enExample) |
| CA (1) | CA2939912C (enExample) |
| MY (2) | MY179845A (enExample) |
| NZ (1) | NZ722492A (enExample) |
| SG (1) | SG11201606106SA (enExample) |
| TW (1) | TWI700493B (enExample) |
| UY (1) | UY36200A (enExample) |
| WO (1) | WO2016003479A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106383231B (zh) * | 2016-09-02 | 2020-03-17 | 四川大学 | 一种诊断肝癌的标记物组合及其应用 |
| GB201619954D0 (en) * | 2016-11-25 | 2017-01-11 | Oncimmune Ltd | Antibody assay |
| KR102175265B1 (ko) | 2019-03-13 | 2020-11-06 | 충남대학교산학협력단 | Txndc7을 포함하는 간세포암종 진단 또는 예후 예측용 바이오마커 조성물 |
| CN110646615B (zh) * | 2019-08-27 | 2021-07-13 | 南方医科大学 | 肝纤维化的生物学标志物、治疗靶点及其用途 |
| WO2023282916A1 (en) | 2021-07-09 | 2023-01-12 | Guardant Health, Inc. | Methods of detecting genomic rearrangements using cell free nucleic acids |
| EP4179111B1 (en) | 2020-07-10 | 2024-04-03 | Guardant Health, Inc. | Methods of detecting genomic rearrangements using cell free nucleic acids |
| CN113502328A (zh) * | 2021-05-27 | 2021-10-15 | 深圳市人民医院 | 检测样本中标志物表达水平的试剂在制备用于检测或诊断乳腺癌的试剂盒中的应用 |
| CN113777295B (zh) * | 2021-09-15 | 2024-03-19 | 江南大学 | 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用 |
| CN113956344A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种新型治疗肝癌的fgf类似物及其应用 |
| CN114113611B (zh) * | 2021-12-13 | 2023-07-14 | 郑州大学 | 一种用于肝癌诊断的生物标志物及检测试剂盒 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6449562B1 (en) | 1996-10-10 | 2002-09-10 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
| US6893844B1 (en) * | 1998-09-22 | 2005-05-17 | Long Yu | DNA encoding a new human hepatoma derived growth factor and producing method thereof |
| US7387881B2 (en) * | 2001-09-19 | 2008-06-17 | The Regents Of The University Of Michigan | Detection and treatment of cancers of the liver |
| WO2003058201A2 (en) * | 2001-12-31 | 2003-07-17 | Quark Biotech, Inc. | Methods for identifying marker genes for cancer |
| GB0228900D0 (en) * | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
| JP3960614B2 (ja) * | 2003-08-31 | 2007-08-15 | 株式会社イムノディア | 抗ペプチド抗体測定法とペプチドワクチンのワクチン候補選択方法 |
| GB0406215D0 (en) * | 2004-03-19 | 2004-04-21 | Procure Therapeutics Ltd | Prostate stem cell |
| CA2567987A1 (en) * | 2004-06-18 | 2005-12-29 | Gabriele Pestlin | Use of protein pdx1 as a marker for breast cancer |
| JP5211315B2 (ja) | 2006-07-25 | 2013-06-12 | 国立大学法人愛媛大学 | 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法 |
| JP5553603B2 (ja) * | 2007-08-10 | 2014-07-16 | 学校法人兵庫医科大学 | 新規肝癌マーカー |
| US8512963B2 (en) * | 2009-11-25 | 2013-08-20 | The Johns Hopkins University | Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples |
| US9523680B2 (en) * | 2010-06-30 | 2016-12-20 | Ambergen, Inc. | Global Proteomic screening of random bead arrays using mass spectrometry imaging |
| JP5493130B2 (ja) | 2010-08-25 | 2014-05-14 | 国立大学法人山口大学 | 自己抗体の検出方法 |
| CA2827894A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| WO2013049704A2 (en) * | 2011-09-28 | 2013-04-04 | Armune Biosciences, Inc. | Method and system of particle-phage epitope complex |
-
2014
- 2014-07-31 CA CA2939912A patent/CA2939912C/en active Active
- 2014-07-31 KR KR1020167032783A patent/KR102086788B1/ko not_active Expired - Fee Related
- 2014-07-31 AU AU2014399919A patent/AU2014399919B2/en not_active Ceased
- 2014-07-31 NZ NZ72249214A patent/NZ722492A/en not_active IP Right Cessation
- 2014-07-31 TW TW103126171A patent/TWI700493B/zh not_active IP Right Cessation
- 2014-07-31 MY MYPI2017001446A patent/MY179845A/en unknown
- 2014-07-31 JP JP2016571689A patent/JP2017520763A/ja active Pending
- 2014-07-31 WO PCT/US2014/049038 patent/WO2016003479A1/en not_active Ceased
- 2014-07-31 EP EP14896556.9A patent/EP3164711A4/en not_active Withdrawn
- 2014-07-31 MY MYPI2016002278A patent/MY195045A/en unknown
- 2014-07-31 SG SG11201606106SA patent/SG11201606106SA/en unknown
-
2015
- 2015-07-01 CN CN201710545890.8A patent/CN107478842B/zh not_active Expired - Fee Related
- 2015-07-01 CN CN201510379493.9A patent/CN105319362B/zh not_active Expired - Fee Related
- 2015-07-01 UY UY0001036200A patent/UY36200A/es unknown
-
2017
- 2017-09-21 AU AU2017232129A patent/AU2017232129B2/en not_active Ceased
-
2020
- 2020-06-22 JP JP2020106731A patent/JP2020160082A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014399919B2 (en) | 2019-10-24 |
| AU2017232129B2 (en) | 2018-10-25 |
| CA2939912A1 (en) | 2016-01-07 |
| JP2017520763A (ja) | 2017-07-27 |
| AU2014399919A1 (en) | 2016-08-11 |
| CA2939912C (en) | 2019-04-16 |
| KR20170021234A (ko) | 2017-02-27 |
| CN105319362B (zh) | 2018-07-13 |
| TWI700493B (zh) | 2020-08-01 |
| EP3164711A1 (en) | 2017-05-10 |
| CN107478842B (zh) | 2020-10-16 |
| CN105319362A (zh) | 2016-02-10 |
| WO2016003479A1 (en) | 2016-01-07 |
| TW201602579A (zh) | 2016-01-16 |
| NZ722492A (en) | 2019-09-27 |
| HK1224370A1 (zh) | 2017-08-18 |
| UY36200A (es) | 2016-01-29 |
| CN107478842A (zh) | 2017-12-15 |
| MY195045A (en) | 2023-01-04 |
| HK1248803A1 (zh) | 2018-10-19 |
| JP2020160082A (ja) | 2020-10-01 |
| KR102086788B1 (ko) | 2020-03-09 |
| EP3164711A4 (en) | 2018-05-23 |
| AU2017232129A1 (en) | 2017-10-12 |
| SG11201606106SA (en) | 2016-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY179845A (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
| WO2014140933A8 (en) | Method for the prognosis and treatment of cancer metastasis | |
| MY188938A (en) | Therapeutic, diagnostic and prognostic methods for cancer of the bladder | |
| WO2015071669A3 (en) | Materials and methods for diagnosis and prognosis of liver cancer | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| EP4574024A3 (en) | Diagnostic and prognostic methods for cardiovascular diseases and events | |
| WO2015176066A3 (en) | Lpa-associated protein and rna expression | |
| EP4356960A3 (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| MX2021006791A (es) | Metodos y composiciones para detectar proteinas mal plegadas. | |
| WO2017062496A3 (en) | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer | |
| TR201907389T4 (tr) | Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem. | |
| Leung et al. | Ovarian cancer biomarkers: current state and future implications from high-throughput technologies | |
| WO2019094780A3 (en) | Non-coding rna for detection of cancer | |
| WO2017027685A3 (en) | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy | |
| SG10201806729VA (en) | Novel assay to detect human periostin | |
| NZ729773A (en) | Biomarkers for disease progression in melanoma | |
| WO2015077382A3 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
| EP3869198A3 (en) | Reagents and methods for breast cancer detection | |
| CY1119430T1 (el) | Anti-s100a7 αντισωματα για τη θεραπευτικη αγωγη και διαγνωση καρκινου | |
| WO2016164468A3 (en) | Human monoclonal autoantibodies to adamts13 and uses thereof | |
| CA2967867C (en) | Methods for detection and treatment of colorectal cancer | |
| WO2015166353A3 (en) | Early detection of preeclampsia | |
| EP4610655A3 (en) | Markers of endometrial cancer | |
| MX2019005940A (es) | Biomarcadores relacionados a cancer. | |
| CA3080263A1 (en) | Method for diagnosing cancer from blood |